» Articles » PMID: 29221196

Identification of Cellular Genes and Pathways Important for Tumorigenicity of Hepatocellular Carcinoma Cell Lines by Proteomic Profiling

Overview
Journal Oncotarget
Specialty Oncology
Date 2017 Dec 10
PMID 29221196
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) is the most commonly diagnosed malignancy of the liver. A more thorough understanding of HCC pathogenesis will provide novel targets for development of cancer drugs to effectively treat HCC. To further this goal, we carried out a proteomic profiling of HCC cell lines Huh-7.4 and Huh-7.5. These two cell lines were derived from subgenomic HCV RNA-replicating Huh-7 cells upon clearance of HCV RNA by antiviral drug treatment. Initially, the tumorigenicity of each cell line was determined and compared in parallel in the same immunedeficient mice. Strikingly, the Huh-7.4 cell line was able to induce tumors, whereas the Huh-7.5 cell line failed to do so, providing unique model systems for identifying cellular genes and pathways important for HCC development and progression. Subsequently, one-dimensional LC-MS/MS proteomic and bioinformatics analyses were performed in the hope of identifying unique cellular genes and pathways responsible for HCC tumorigenicity. Interestingly, a total of 130 cellular genes were found to be significantly up- or downregulated between these two cell lines (r>3 fold, P<0.001). Also, EIF (EIF2&4), mTOR/p70S6K, ERK5, and EGFR signaling pathways were significantly different. Overall, these results provide significant new information to shed light on the underlying biological processes involved in HCC development and progression.

Citing Articles

Impact of ERK5 on the Hallmarks of Cancer.

Stecca B, Rovida E Int J Mol Sci. 2019; 20(6).

PMID: 30901834 PMC: 6471124. DOI: 10.3390/ijms20061426.

References
1.
Rovida E, Maira G, Tusa I, Cannito S, Paternostro C, Navari N . The mitogen-activated protein kinase ERK5 regulates the development and growth of hepatocellular carcinoma. Gut. 2014; 64(9):1454-65. DOI: 10.1136/gutjnl-2014-306761. View

2.
Bruix J, Sherman M . Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53(3):1020-2. PMC: 3084991. DOI: 10.1002/hep.24199. View

3.
Liu S, Yang Z, Wei H, Shen W, Liu J, Yin Q . Increased DJ-1 and its prognostic significance in hepatocellular carcinoma. Hepatogastroenterology. 2011; 57(102-103):1247-56. View

4.
Ding S, Li Y, Shao X, Zhou H, Zeng R, Tang Z . Proteome analysis of hepatocellular carcinoma cell strains, MHCC97-H and MHCC97-L, with different metastasis potentials. Proteomics. 2004; 4(4):982-94. DOI: 10.1002/pmic.200300653. View

5.
Chen F, Zhu H, Zhou L, Wu S, Wang J, Chen Z . IQGAP1 is overexpressed in hepatocellular carcinoma and promotes cell proliferation by Akt activation. Exp Mol Med. 2010; 42(7):477-83. PMC: 2912475. DOI: 10.3858/emm.2010.42.7.049. View